Annalisa Morelli
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Annalisa Morelli has a total of 77 co-authors. Here are the top co-authors by number of shared publications:
- Paolo Bigini
Department of Molecular Biochemistry and Pharmacology, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Via Mario Negri 2, 20156 Milano, Italy
5 shared publications - Martina Bruna Violatto
Department of Molecular Biochemistry and Pharmacology Istituto di Ricerche Farmacologiche Mario Negri IRCCS Via Mario Negri 2 Milano 20156 Italy
3 shared publications - Alberto Martinez-Serra
Barcelona Supercomputing Center (BSC), Barcelona, Spain
2 shared publications - Fabio Fiordaliso
Department of Molecular Biochemistry and Pharmacology, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Via Mario Negri 2, 20156 Milano, Italy
2 shared publications - Giovanni Sitia
Division of Immunology, Transplantation and Infectious Diseases, IRCCS San Raffaele Scientific Institute, 20132 Milan, Italy
2 shared publications - Giulia Yuri Moscatiello
Department of Biochemistry and Molecular Pharmacology, Istituto di Ricerche Farmacologiche "Mario Negri" IRCCS, Milano, Italy
2 shared publications
Latest Publications
- Open Access
- 20 April 2026
- Published by Royal Society of Chemistry (RSC) in Nanoscale Advances
- Vol. 8 (9) , 2865-2891
Navigating the Nanoverse : how emerging nanomaterials are transforming bioscience and society
This review navigates the Nanoverse , an expanding dimension that connects emerging nanoscale materials with medicine, biosensing, and safety, highlighting how innovation, regulation, and ethics converge to guide nanotechnology for a better society.
- 20 April 2026
- Published by Royal Society of Chemistry (RSC) in Nanoscale Advances
- Vol. 8 (9) , 2865-2891
Open AccessNavigating the Nanoverse : how emerging nanomaterials are transforming bioscience and society
This review navigates the Nanoverse , an expanding dimension that connects emerging nanoscale materials with medicine, biosensing, and safety, highlighting how innovation, regulation, and ethics converge to guide nanotechnology for a better society.
- Open Access
- 24 November 2025
- Published by Springer Nature in BMC Pulmonary Medicine
- Vol. 25 (1) , 543
Optimization of intranasal bleomycin dose for effective pulmonary fibrosis induction in mice with minimal animal distress
Pulmonary fibrosis is a progressive interstitial lung disease driven by aberrant alveolar epithelial repair and dysregulated crosstalk with mesenchymal cells, leading to myofibroblast activation and excessive extracellular matrix deposition. Current mouse models for studying its pathogenesis often use invasive methods like intratracheal bleomycin administration, which can cause significant animal distress. This study aims to refine the bleomycin model via intranasal instillation, reducing animal suffering while improving reproducibility and translational value. The MALDI-TOF MS analysis allowed for the identification of the spatial distribution of bleomycin directly on the lung tissue of C57BL/6 J mice after intranasal administration to demonstrate the effectiveness of this route. Different doses (1, 3, 5 mg/kg) of bleomycin were tested in mice. Non-invasive whole-body plethysmography enabled the monitoring of the disease progression and the assessment of pulmonary function in conscious mice. Histopathological analyses were performed to follow fibrosis progression. This method resulted in impaired respiratory function, with a similar pattern observed for both 5 and 3 mg/kg doses. Histopathological evaluations revealed rapid acute inflammation followed by chronic fibrosis in both dosage groups, similar to human IPF. Key molecular markers (CD68 and COL 1a1) were upregulated in response to the treatment, with similar expression patterns between the two doses, suggesting an inflammatory response and established fibrosis. 1 mg/kg dosage did not lead to any relevant clinical changes and was therefore excluded from further analyses. Intranasal administration proved to be an efficient technique, delivering a uniform bleomycin distribution in the lungs. Bleomycin instillation induced lung injury and fibrosis comparable to those achieved with the conventional intratracheal protocol, both histologically and functionally, while reducing invasiveness and animal distress. The optimal bleomycin dosage was determined to be 3 mg/kg, which induced a similar level of respiratory distress, but with less weight loss and reduced risk of mortality. This approach provides a reproducible model for preclinical studies of pulmonary fibrosis. This strategy ensures consistent and reproducible scientific data, pivotal for bridging the gap between benchside and bedside.
- 24 November 2025
- Published by Springer Nature in BMC Pulmonary Medicine
- Vol. 25 (1) , 543
Open AccessOptimization of intranasal bleomycin dose for effective pulmonary fibrosis induction in mice with minimal animal distress
Pulmonary fibrosis is a progressive interstitial lung disease driven by aberrant alveolar epithelial repair and dysregulated crosstalk with mesenchymal cells, leading to myofibroblast activation and excessive extracellular matrix deposition. Current mouse models for studying its pathogenesis often use invasive methods like intratracheal bleomycin administration, which can cause significant animal distress. This study aims to refine the bleomycin model via intranasal instillation, reducing animal suffering while improving reproducibility and translational value. The MALDI-TOF MS analysis allowed for the identification of the spatial distribution of bleomycin directly on the lung tissue of C57BL/6 J mice after intranasal administration to demonstrate the effectiveness of this route. Different doses (1, 3, 5 mg/kg) of bleomycin were tested in mice. Non-invasive whole-body plethysmography enabled the monitoring of the disease progression and the assessment of pulmonary function in conscious mice. Histopathological analyses were performed to follow fibrosis progression. This method resulted in impaired respiratory function, with a similar pattern observed for both 5 and 3 mg/kg doses. Histopathological evaluations revealed rapid acute inflammation followed by chronic fibrosis in both dosage groups, similar to human IPF. Key molecular markers (CD68 and COL 1a1) were upregulated in response to the treatment, with similar expression patterns between the two doses, suggesting an inflammatory response and established fibrosis. 1 mg/kg dosage did not lead to any relevant clinical changes and was therefore excluded from further analyses. Intranasal administration proved to be an efficient technique, delivering a uniform bleomycin distribution in the lungs. Bleomycin instillation induced lung injury and fibrosis comparable to those achieved with the conventional intratracheal protocol, both histologically and functionally, while reducing invasiveness and animal distress. The optimal bleomycin dosage was determined to be 3 mg/kg, which induced a similar level of respiratory distress, but with less weight loss and reduced risk of mortality. This approach provides a reproducible model for preclinical studies of pulmonary fibrosis. This strategy ensures consistent and reproducible scientific data, pivotal for bridging the gap between benchside and bedside.
- Open Access
- 22 April 2025
- Published by Royal Society of Chemistry (RSC) in Environmental Science: Nano
- Vol. 12 (5) , 2857-2870
The surface charge both influences the penetration and safety of polystyrene nanoparticles despite the protein corona formation
Above other physical and chemical features, the surface charge of PS-NPs is crucial for their interaction with cells and biological effects in C. elegans.
- 22 April 2025
- Published by Royal Society of Chemistry (RSC) in Environmental Science: Nano
- Vol. 12 (5) , 2857-2870
Open AccessThe surface charge both influences the penetration and safety of polystyrene nanoparticles despite the protein corona formation
Above other physical and chemical features, the surface charge of PS-NPs is crucial for their interaction with cells and biological effects in C. elegans.
- Open Access
- 14 February 2025
- Published by Wiley in Advanced Science
- Vol. 12 (16) , e2407458
Functional Polarization of Liver Macrophages by Glyco Gold Nanoparticles
Macrophages are crucial drivers of innate immunity. Reprogramming macrophages to a restorative phenotype in cancer or autoimmune diseases can stop their cancer‐promoting activity or trigger anti‐inflammatory immunity. Glycans have emerged as key components for immunity as they are involved in many pathophysiological disorders. Previous studies have demonstrated that supraphysiological amounts of mannose (Man) or sialic acid (Sia) can inhibit tumor growth and stimulate differentiation of regulatory T cells. Man is known to affect glucose metabolism in glycolysis by competing for the same intracellular transporters and affecting macrophage polarization, whereas Sia alters macrophage differentiation via signaling through Siglec‐1. Herein, this work describes a macrophage targeting platform using gold nanoparticles (GNPs) functionalized with Man and Sia monosaccharides which exhibit high liver tropism. A single dose of glyco‐GNPs can convert macrophages to a restorative phenotype in two completely different immune environments. Man promotes tumor‐associated macrophages toward an antitumorigenic activity in a MC38 liver colorectal cancer model by secretion of TNF‐α, IL ‐1β, and IL ‐6 in the tumor microenvironment. However, in a proinflammatory environment, as observed in a mouse model of autoimmune disease, primary biliary cholangitis, Man impairs the production of TNF‐α, IL‐1β, Arg1, and IL‐6 cytokines. The results probe the dual role of Man in macrophage repolarization in response to the immune system. This study is a proof‐of‐concept that demonstrates that nanomedicine using specific glycans designed to target other immune cells such as myeloid cells, are a promising strategy not only against cancer but also against other pathologies such as autoimmune diseases.
- 14 February 2025
- Published by Wiley in Advanced Science
- Vol. 12 (16) , e2407458
Open AccessFunctional Polarization of Liver Macrophages by Glyco Gold Nanoparticles
Macrophages are crucial drivers of innate immunity. Reprogramming macrophages to a restorative phenotype in cancer or autoimmune diseases can stop their cancer‐promoting activity or trigger anti‐inflammatory immunity. Glycans have emerged as key components for immunity as they are involved in many pathophysiological disorders. Previous studies have demonstrated that supraphysiological amounts of mannose (Man) or sialic acid (Sia) can inhibit tumor growth and stimulate differentiation of regulatory T cells. Man is known to affect glucose metabolism in glycolysis by competing for the same intracellular transporters and affecting macrophage polarization, whereas Sia alters macrophage differentiation via signaling through Siglec‐1. Herein, this work describes a macrophage targeting platform using gold nanoparticles (GNPs) functionalized with Man and Sia monosaccharides which exhibit high liver tropism. A single dose of glyco‐GNPs can convert macrophages to a restorative phenotype in two completely different immune environments. Man promotes tumor‐associated macrophages toward an antitumorigenic activity in a MC38 liver colorectal cancer model by secretion of TNF‐α, IL ‐1β, and IL ‐6 in the tumor microenvironment. However, in a proinflammatory environment, as observed in a mouse model of autoimmune disease, primary biliary cholangitis, Man impairs the production of TNF‐α, IL‐1β, Arg1, and IL‐6 cytokines. The results probe the dual role of Man in macrophage repolarization in response to the immune system. This study is a proof‐of‐concept that demonstrates that nanomedicine using specific glycans designed to target other immune cells such as myeloid cells, are a promising strategy not only against cancer but also against other pathologies such as autoimmune diseases.
- Open Access
- 31 January 2025
- Published by Beilstein Institut in Beilstein Journal of Nanotechnology
- Vol. 16 (1) , 97-118
Nanocarriers and macrophage interaction: from a potential hurdle to an alternative therapeutic strategy
In the coming decades, the development of nanocarriers (NCs) for targeted drug delivery will mark a significant advance in the field of pharmacology. NCs can improve drug solubility, ensure precise distribution, and enable passage across biological barriers. Despite these potential advantages, the interaction with many biological matrices, particularly with existing macrophages, must be considered. In this review, we will explore the dual role of macrophages in NC delivery, highlighting their physiological functions, the challenges posed by the mononuclear phagocyte system, and innovative strategies to exploit macrophage interactions for therapeutic advantage. Recent advancements in treating liver and lung diseases, particularly focusing on macrophage polarization and RNA-based therapies, have highlighted the potential developments in macrophage–NC interaction. Furthermore, we will delve into the intriguing potential of nanomedicine in neurology and traumatology, associated with macrophage interaction, and the exciting possibilities it holds for the future.
- 31 January 2025
- Published by Beilstein Institut in Beilstein Journal of Nanotechnology
- Vol. 16 (1) , 97-118
Open AccessNanocarriers and macrophage interaction: from a potential hurdle to an alternative therapeutic strategy
In the coming decades, the development of nanocarriers (NCs) for targeted drug delivery will mark a significant advance in the field of pharmacology. NCs can improve drug solubility, ensure precise distribution, and enable passage across biological barriers. Despite these potential advantages, the interaction with many biological matrices, particularly with existing macrophages, must be considered. In this review, we will explore the dual role of macrophages in NC delivery, highlighting their physiological functions, the challenges posed by the mononuclear phagocyte system, and innovative strategies to exploit macrophage interactions for therapeutic advantage. Recent advancements in treating liver and lung diseases, particularly focusing on macrophage polarization and RNA-based therapies, have highlighted the potential developments in macrophage–NC interaction. Furthermore, we will delve into the intriguing potential of nanomedicine in neurology and traumatology, associated with macrophage interaction, and the exciting possibilities it holds for the future.
- Open Access
- 25 March 2023
- Published by MDPI AG in Nanomaterials
- Vol. 13 (7) , 1174
Variations in Biodistribution and Acute Response of Differently Shaped Titania Nanoparticles in Healthy Rodents
Titanium dioxide nanoparticles (TiO2 NPs) are one of the main sources of the nanoparticulate matter exposure to humans. Although several studies have demonstrated their potential toxic effects, the real nature of the correlation between NP properties and their interaction with biological targets is still far from being fully elucidated. Here, engineered TiO2 NPs with various geometries (bipyramids, plates, and rods) have been prepared, characterized and intravenously administered in healthy mice. Parameters such as biodistribution, accumulation, and toxicity have been assessed in the lungs and liver. Our data show that the organ accumulation of TiO2 NPs, measured by ICP-MS, is quite low, and this is only partially and transiently affected by the NP geometries. The long-lasting permanence is exclusively restricted to the lungs. Here, bipyramids and plates show a higher accumulation, and interestingly, rod-shaped NPs are the most toxic, leading to histopathological pulmonary alterations. In addition, they are also able to induce a transient increase in serum markers related to hepatocellular injury. These results indicate that rods, more than bipyramidal and spherical geometries, lead to a stronger and more severe biological effect. Overall, small physico-chemical differences can dramatically modify both accumulation and safety.
- 25 March 2023
- Published by MDPI AG in Nanomaterials
- Vol. 13 (7) , 1174
Open AccessVariations in Biodistribution and Acute Response of Differently Shaped Titania Nanoparticles in Healthy Rodents
Titanium dioxide nanoparticles (TiO2 NPs) are one of the main sources of the nanoparticulate matter exposure to humans. Although several studies have demonstrated their potential toxic effects, the real nature of the correlation between NP properties and their interaction with biological targets is still far from being fully elucidated. Here, engineered TiO2 NPs with various geometries (bipyramids, plates, and rods) have been prepared, characterized and intravenously administered in healthy mice. Parameters such as biodistribution, accumulation, and toxicity have been assessed in the lungs and liver. Our data show that the organ accumulation of TiO2 NPs, measured by ICP-MS, is quite low, and this is only partially and transiently affected by the NP geometries. The long-lasting permanence is exclusively restricted to the lungs. Here, bipyramids and plates show a higher accumulation, and interestingly, rod-shaped NPs are the most toxic, leading to histopathological pulmonary alterations. In addition, they are also able to induce a transient increase in serum markers related to hepatocellular injury. These results indicate that rods, more than bipyramidal and spherical geometries, lead to a stronger and more severe biological effect. Overall, small physico-chemical differences can dramatically modify both accumulation and safety.
- Open Access
Development of a Nanoparticle-Based Approach for the Blood–Brain Barrier Passage in a Murine Model of Amyotrophic Lateral Sclerosis
The development of nanoparticles (NPs) to enable the passage of drugs across blood–brain barrier (BBB) represents one of the main challenges in neuropharmacology. In recent years, NPs that are able to transport drugs and interact with brain endothelial cells have been tested. Here, we investigated whether the functionalization of avidin-nucleic-acid-nanoassembly (ANANAS) with apolipoprotein E (ApoE) would allow BBB passage in the SOD1G93A mouse model of amyotrophic lateral sclerosis. Our results demonstrated that ANANAS was able to transiently cross BBB to reach the central nervous system (CNS), and ApoE did not enhance this property. Next, we investigated if ANANAS could improve CNS drug delivery. To this aim, the steroid dexamethasone was covalently linked to ANANAS through an acid-reversible hydrazone bond. Our data showed that the steroid levels in CNS tissues of SOD1G93A mice treated with nanoformulation were below the detection limit. This result demonstrates that the passage of BBB is not sufficient to guarantee the release of the cargo in CNS and that a different strategy for drug tethering should be devised. The present study furthermore highlights that NPs can be useful in improving the passage through biological barriers but may limit the interaction of the therapeutic compound with the specific target.
Open AccessDevelopment of a Nanoparticle-Based Approach for the Blood–Brain Barrier Passage in a Murine Model of Amyotrophic Lateral Sclerosis
The development of nanoparticles (NPs) to enable the passage of drugs across blood–brain barrier (BBB) represents one of the main challenges in neuropharmacology. In recent years, NPs that are able to transport drugs and interact with brain endothelial cells have been tested. Here, we investigated whether the functionalization of avidin-nucleic-acid-nanoassembly (ANANAS) with apolipoprotein E (ApoE) would allow BBB passage in the SOD1G93A mouse model of amyotrophic lateral sclerosis. Our results demonstrated that ANANAS was able to transiently cross BBB to reach the central nervous system (CNS), and ApoE did not enhance this property. Next, we investigated if ANANAS could improve CNS drug delivery. To this aim, the steroid dexamethasone was covalently linked to ANANAS through an acid-reversible hydrazone bond. Our data showed that the steroid levels in CNS tissues of SOD1G93A mice treated with nanoformulation were below the detection limit. This result demonstrates that the passage of BBB is not sufficient to guarantee the release of the cargo in CNS and that a different strategy for drug tethering should be devised. The present study furthermore highlights that NPs can be useful in improving the passage through biological barriers but may limit the interaction of the therapeutic compound with the specific target.